Store your own stem cells today for tomorrow! With your decision you will be amongst those who are already open to all future medical options.

TICEBA - Advantages at a glance - Picture 01TICEBA - Advantages at a glance - Picture 02

Our Exclusive Service Contains

  • Removal and storage of the cells from the skin and the stem cells contained therein
  • Preparation
  • Cryogenic storage and conservation of the skin tissue with the stem cells contained therein

Process of Sampling and Conservation

In a short ambulant surgery the required piece of skin with a size of about 5 cm² (2 in²) is obtained from a cosmetically inconspicuous place, e.g. from behind the ear.

The subsequent preparation of the tissue occurs for the purpose of preparation of the cryoconservation of the cells in liquid nitrogen.

Freezing of the cells is carried out in accordance with the latest technical and scientific standard in our cryostorage tanks at up to -196 degrees Celsius (-320.8 degrees Fahrenheit) where the treated skin tissue is safely stored.

TICEBA - Process of Sampling and Conservation

Application of Stem Cells

In the case of medical need, we retrieve your stem cells as well as your tissue. If this case occurs, just get in touch with us. We assure that your tissue with the stem cells contained therein is available at the right place at the right time.

Clinical Trial - EB

The trial has been approved by the U.S. Food and Drug Administration (FDA) and the other respective competent national regulatory authorities and has recently been granted Orphan Drug Designation for the treatment of RDEB in the EU and the USA.

Clinical Trial - LSCD

For the international and FDA approved clinical trial for the limbal stem cell medicinal product LSC2 our daughter company RHEACELL recently received Orphan Drug Designation status in the EU for the treatment of limbal stem cell deficiency (LSCD) and Fast Track Designation in the USA. More information can be found HERE and HERE.

Clinical Trials

Our subsidiary RHEACELL is recruiting patients for further clinical trials in phase I/IIa with allogeneic ABCB5-positive (ABCB5+) mesenchymal stem cells for the indications chronic venous ulcers (CVU), diabetic foot ulcers (DFU), peripheral arterial occlusive disease (PAOD), epidermolysis bullosa (EB) and acute on chronic liver failure (ACLF) and with allogeneic ABCB5+ limbal stem cells for the indication limbal stem cell deficiency (LSCD). For more information click HERE.


In a comprehensive preclinical study program, safety and local tolerability of ABCB5+ MSCs following subcutaneous, intramuscular and intravenous application has been demonstrated (Tappenbeck et al., 2019).